Blood Lipids and Its Atherogenic Indices in Alloxan Induced Diabetic Male Rats

Main Article Content

O. D. Chikezie
S. C. Meludu
I. S. I. Ogbu
B. N. Egejuru
T. Ude
O. Ekuma-Ogbonnia


Background: Diabetes mellitus is a group of metabolic disorders which result to excessive accumulation of blood sugar over a prolonged period. Due to higher risk of diabetes mellitus to cardiovascular disease, it is crucial to identify and address these cardiovascular risks. This study assessed the effects of diabetes on levels of some blood lipids and its atherogenic indices in diabetic male rats.

Methods: This is an experimental study that involved 40 apparently healthy adult male albino rats (wistar strain) which were randomly assigned to five groups (A, B, C, D and E) of eight (8) animals each. Group A (Normal Control of No intervention for 72 hours), Group B (Diabetic rats of 72 hours post diabetes induction), Group C (metformin treated diabetic rats), Group D (Diabetic Control untreated) and Group E (Normal Control of 3 weeks post diabetes induction). Seven milliliters of fasting blood sample were collected from all the subjects. Serum levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c) and very low density lipoprotein cholesterol (VLDL-c) were determined using standard methods. Atherogenic indices, non HDL cholesterol (Non HDL-c), cardio risk ratio (CRR), atherogenic index of plasma (AIP), atherogenic coefficient (AC) and atherosclerosis index (AI) were calculated. It was analyzed statistically using SPSS version 23.0.

Results: The mean values of HDL-c was significantly higher in the treated diabetic group when compared with untreated diabetic control (P<0.05) while TC, TG, LDL-c, VLDL-c, Non HDL-c, CRR, AIP, AC and AI were significantly lower in treated diabetics when compared to the untreated diabetic control (P<0.05). Also, blood mean levels of HDL-c were significantly lower in the diabetic groups (treated and untreated) when compared with non diabetic control (P<0.05) while TC, TG, LDL-c, VLDL-c, Non HDL-c, CRR, AIP, AC and AI were significantly higher in the diabetic groups (treated and untreated) when compared with non diabetic control (P<0.05).

Conclusion: The study suggests that atherogenic indices can serve as predictive pointer for future cardiovascular event especially, when LDLc value is normal. Also hyperglycemia could cause significant alterations of lipids, but metformin treatment has showed not only hypoglycemic effect, but also anti-hyperlipidemic properties.

Lipid profile, dyslipidaemia, atherogenic indices, rats.

Article Details

How to Cite
Chikezie, O. D., Meludu, S. C., Ogbu, I. S. I., Egejuru, B. N., Ude, T., & Ekuma-Ogbonnia, O. (2020). Blood Lipids and Its Atherogenic Indices in Alloxan Induced Diabetic Male Rats. Asian Journal of Advanced Research and Reports, 9(2), 25-33.
Original Research Article


American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care. 2004;27(1):5–14.

Alebiosu CO. Clinical diabetic nephropathy in a tropical African population. West African Journal of Medicine. 2003;22(2): 152-155.

Kasiam LO, Long-Mbenza B, Nge OA, Kangola KN, Mbungu FS, Milongo DG. Classification and dramatic epidemic of diabetes mellitus in Kinshasa hinterland: The prominent role of type 2 diabetes and lifestyles changes among Africans. Nigerian Journal of Medicine. 2009;18(3): 311-320.

Menik HL, Sammanthi JS, Priyantha WT, Wijewickrama GS, Shalika P, Kotapola I. Significant genetic association between insulin resistance and total cholesterol in type 2 diabetes mellitus- A Preliminary Observation. Online Journal of Health and Allied Sciences. 2005;4(1).

Emerging Risk Factors Collaboration, Sarwar N, Gao P, Kondapally Seshasai SR, Gobin R, Kaptoge K, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. The Lancet. 2010;375(9733):2215–2222.

Eschwe’ge E. The dysmetabolic syndrome, insulin resistance and increase in cardiovascular mortality and morbidity in type 2 diabetes: etiological factors in the development of cardiovascular complications. Diabetes Metabolism. 2003; 29(4-2):6519-6527.

National Cholesterol Education Program (NCEP) Expert Panel. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-3421.

VinodMahato R, Gyawali P, Raut PP, Regmi P, Singh KP, Pandeya DR, Gyawali P. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycatedhaemoglobin as a dual biomarker. Biomedical Research. 2011;22 (3):375-380.

Swaminathan S, Priya G, Revathy K, Emila S. Non HDL-C as an alternate to LDL-C for the diagnosis of cardio vascular disease. Journal Pharmaceutical and Biomedical Sciences. 2013;30(30):913-919.

Adu EM, Ukwamedu HA, Oghagbon ES. Assessment of cardiovascular risk indices in type 2 diabetes mellitus. Tropical Medicine and Surgery. 2015;3(2):184.
DOI: 10.4172/2329-9088.1000184

Ikewuchi CC. Effect of Aqueous Extract of Sansevieria senegambica baker on plasma chemistry, lipid profile and atherogenic indices of alloxan treated rats: implications for the management of cardiovascular complications in diabetes mellitus. Pacific Journal of Science and Technology. 2010; 11:524-531.

Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi S. Atherogenic index of plasma, Castelli risk index and atherogenic coefficient- new parameters in assessing cardiovascular risk. International Journal of Pharma and Bio Sciences. 2013;3(3):359-364.

Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascularrisk among postmenopausal women in Enugu, Nigeria. African Health Sciences. 2010;10(3):248–252.

Cai G, Shi G, Xue S, Lu W. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96(37):8058.

Dobiásová M, Frohlich J, Sedová M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. Journal of Lipid Research. 2011;52(3):566-571.

Song P, Xu L, Xu J, Zhang HQ, Yu CX, Guan QB, Zhao M, Zhang X. Atherogenic index of plasma is associated with body fat level in type 2 diabetes mellitus patients. Current Vascular Pharmacology. 2018; 16(6):589–595.

Srisawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, Vanavanan S, Kroll, MH. Estimation of plasma small dense LDL cholesterol from classic lipid measures. American Journal of Clinical Pathology. 2011;136(1):20-29.

Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. American Journal of Cardiology. 2008;101 (7):1003-1008.

Dallatu MK, Anaja PO, Bilbis LS, Mojiminiyi FBO, Mohammed A, Tanko Y. Hematological and antioxidant properties of alloxan-induced diabetes rats supplemented with antioxidant micronutrients. Nigerian Journal of Basic and Applied Science. 2010;18(1):106-111.

Mule VS, Naikwade NS, Magdum CS, Jagtap VA. Antidiabetic activity of extracts of Pithecellobium dulce Benth leaves in alloxan induced diabetic rats. International Journal of Pharmaceutical Sciences and Drug Research. 2016;8(5):275–280.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1990; 36(7):15 -19.

Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB lipoprotein depleted plasma (FER (HDL). Clinical Biochemistry. 2001; 34(7):583-588.

Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clinical Chemistry. 2004;50(12): 2316-2322.

Harini DN, Ambika DK, Prabath KD, Vani N. Lipid ratios, atherogenic coefficient and atherogenic index of plasma as parameters in assessing cardiovascular risk in type 2 diabetes mellitus. International Journal of Research in Medical Sciences. 2016;4(7):2863-2869.

Suchitra MM, Sheshu KM, Bitla AR, Rao AM, Alok S. Atherogenic dyslipidemia in diabetic nephropathy: lipoprotein: A lipid ratios and atherogenic index. International Journal of Research in Medical Sciences. 2013;1(4):455-459.

Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clinical Chemistry. 1982;28(10):2077-2080.

Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clinical Chemistry. 1974;20(4):470-475.

Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. Scandinavian Journal of Clinical and Laboratory Investigation. 1980;40:583-595.

Levesque R. A guide for SPPSS and SAS users, SPSS programming and data management, (4th edition), 233 south wacker drive, 11th floor, Chicago, United State of America. 2007;2-540.

Azizi R, Salemi Z, Goodarzi MT. Effect of Biochanin - A on serum visfatin levels in STZ-induced diabetic rats. Iran Red Crescent Medical Journal. 2014;16(9):1–7.

Pierre W, Gildas AJ, Ulrich MC, Modeste WN, Benoit NT, Albert K. Hypoglycemic and hypolipidemic effects of Bersama engleriana leaves in nicotinamide/ streptozotocin-induced type 2 diabetic rats. BMC Complementary and Alternative Medicine. 2012;12:264.

Vishnu PC, Ketkee PG, Anil TP. Antidiabetic, antihyperlipidemic activities and herb–drug interaction of a polyherbal formulation in streptozotocin induced diabetic rats. Journal of Ayurveda and Integrative Medicine. 2017;8(4):218–225.

Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG. Weight management through lifestyle modification for the prevention of type 2 diabetes: Rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity and the American Society for Clinical Nutrition. American Journal of Clinical Nutrition. 2004;80(2):257-263.

Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496-1504.

Manjusha KB, Ipseeta RM, Ujwala M, Rajesh KS, Deshmukh YA. Myocardial salvaging effects and mechanisms of metformin in experimental diabetes. International Journal of Basic and Clinical Pharmacology. 2016;5(2):341- 349.

Rajesh KS, Ipseeta RM, Ujawala M, Manjusha KB, Deshmukh, YA. Metformin ameliorates diabetes with metabolic syndrome induced changes in experimental rats. International Journal of Biomedical Research. 2016;7(2):55-65.

Hundal RS, Inzucchi SE. Metformin new understandings, new uses. Drugs. 2003; 63(18):1879–1894.

Viollet B, Guigas B, Leclerc J, Hebrard S, Lantier L, Mounier R, Andreelli F, Foretz M. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiologica. 2009;196 (1):81–90.

Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Revives, Molecular Cellular Biology. 2012;13(4): 251–262.

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. Journal of Clinical Investigation. 2010;120(7):2355–2369.